GATA-1 DNA Binding Activity Is Down-regulated in Late S Phase in Erythroid Cells*

(Received for publication, October 28, 1996)

Martin E. Cullen Dagger and Roger K. Patient §

From the Developmental Biology Research Centre, The Randall Institute, King's College London, 26-29 Drury Lane, London WC2B 5RL, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

We have set out to test a model for tissue-specific gene expression that relies on the early replication of expressed genes to sequester limiting activating transcription factors. Using an erythroid cell line, we have tested the changes in the DNA binding activity of the lineage-restricted transcription factor GATA-1 through the cell cycle. We find that GATA-1 activity is low in G1, peaks in mid-S phase, and then decreases in G2/M. In contrast, the binding activities of two ubiquitous transcription factors, Oct1 and Sp1, remain high in G2/M. GATA-1 protein and mRNA vary in a similar manner through the cell cycle, suggesting that the expression of the gene or the stability of its message is regulated. Although a number of transcription factors involved in the control of the cell cycle or DNA replication have been shown to peak in S phase, this is the first example of a lineage-restricted transcription factor displaying S phase-specific DNA binding activity. One interpretation of these data leads to a model in which the peak in GATA-1 DNA binding amplifies the effect of early replication on the activation of erythroid-specific genes at the same time as preventing activation of non-erythroid genes containing GATA-responsive elements. These results may also relate to recent data implicating GATA-1 function in apoptosis and cell cycle progression.


INTRODUCTION

The relationship between cell division and differentiation is still unclear. In the hematopoietic system, it has long been thought that differentiation requires prior or concomitant cell division (1), but direct evidence for a mechanistic relationship has been hard to obtain. One potential mechanism involves the effect of DNA replication on repressive chromatin and stable transcription complexes. The passage of a replication fork through a chromatin template is known to transiently disrupt both histone octamers and complexes of transacting factors required for programming gene expression (2, 3). Subsequently, as nucleosomes reform behind the replication fork, transcription factors have a window of opportunity to bind and either reprogram gene expression or reassemble committed genes (2, 4, 5).

Evidence in support of a role for DNA replication in gene activation for a variety of viral and cellular genes has been provided by the activating effect of an origin of replication in transient transfection assays (6-9). Furthermore, in the normal cellular context, a strong correlation exists between the replication timing of a gene and its state of transcriptional activity. Specifically, replication early in S phase is associated with expression for a large number of tissue-specific genes in a variety of different cell types (10-13). A well studied example is the beta  globin locus, which is replicated early in erythroid cells where it is transcribed but late in fibroblasts where it is not (13, 14). The major determinant of erythroid expression of this locus is the locus control region, a set of nuclease hypersensitive sites located several kilobases upstream of the first gene in the cluster. The locus control region is required both for transcription and early replication of the beta  globin locus (15), further maintaining the correlation between replication timing and tissue-specific gene activation, leading to a model where early replication removes repressive chromatin and allows activating transcription factors to bind (4, 16). Transcription factor availability is clearly an important component of such a model. If the overall nuclear concentration of critical factors remained constant in the cell cycle, titration of transcription factors by early replicating genes would limit their availability for binding to later replicating genes with the same control sequences, as has been suggested for the early replicating somatic 5 S RNA genes of Xenopus (4, 17, 18). Alternatively, sequestration of transcription factors to prevent activation of genes replicating in late S phase would be further enhanced by a concomitant decrease in factor DNA binding activity. These considerations have led to the suggestion that fluctuations in the levels of critical transacting factors during S phase may amplify the effect on chromatin remodeling conferred by early replication (6).

We have set out to test this model, using an erythroid cell line that contains both a transcriptionally poised beta  globin gene that replicates during the first half of S phase (14, 19) and GATA-1, a lineage-restricted transcription factor crucial for erythroid differentiation (20, 21) that has potential binding sites in the regulatory sequences of all erythroid genes (22) and is expressed at increasingly higher levels during erythroid maturation (23). We find that the availability of GATA-1 but not ubiquitous factors does indeed vary in the cell cycle in a manner likely to amplify the effects of replication timing. GATA-1 therefore represents a candidate molecule for linking erythroid transcription and early replication. These data can also be linked with recent observations that GATA-1 may be directly involved in control of the cell cycle and the choice among proliferation, differentiation, and apoptosis (24-26).


EXPERIMENTAL PROCEDURES

Cell Culture and Cell Cycle Fractionation

MEL1 cells (27) were grown in RPMI 1640 supplemented with 2 mM glutamine and 10% fetal calf serum in 37 °C incubators containing 5% CO2. Asynchronous log phase cells were separated into different stages of the cell cycle by centrifugal elutriation, as follows. 108-109 cells were pelleted, washed in phosphate-buffered saline, resuspended at a concentration of approximately 107 cells/ml, and injected into the chamber of a Beckman JE-5.0 elutriation rotor spinning at 3000 rpm containing ice-cold phosphate-buffered saline pumped at 21 ml/min. The pump rate was incremented in 10-15 steps up to 65 ml/min, and elutriated fractions were collected onto ice. Fractions were then pelleted, resuspended in 5 ml of phosphate-buffered saline, and analyzed by Coulter counter to determine cell concentration and size distribution. Aliquots of 5 × 105 cells were removed, stained with propidium iodide (28), and analyzed by FACS to determine the quality of the elutriation. Adjacent fractions that consisted of essentially identical cell cycle profiles were pooled, and nuclear proteins were then extracted.

Cell Extracts

Elutriated cells were pelleted and then taken up at constant cell concentration in ice-cold 20 mM Hepes, pH 7.0, 2 mM MgCl2 containing 0.05% Triton X-100, and a mixture of protease (5 mM benzamidine, 5 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml pepstatin, 2 µg/ml aprotinin, 5 µg/ml bestatin), kinase (0.5 mM EDTA), and phosphatase (1 M beta -glycerophosphate, 0.2 M levamisole, 0.25 M NaF, 20 mM sodium vanadate) inhibitors. After incubation on ice for 15 min, lysed cells were pelleted at 6500 rpm in a microfuge for 2 min at 4 °C, and the pelleted nuclei were resuspended in 2 volumes of 20 mM Hepes, pH 7.0, 2 mM MgCl2 containing 350 mM NaCl plus inhibitors. After 15 min on ice, nuclear debris was removed by centrifugation at 14000 rpm for 10 min. Glycerol was added to the supernatants to 25%, and aliquots were flash frozen and stored at -70 °C.

Electophoretic Mobility Shift Assays

Nuclear extracts (0.2-4 µl) were mixed with 7.5 µl of 4 × buffer (20 mM Hepes, pH 7.9, 2 mM MgCl2, 50 mM NaCl, 4% w/v Ficoll), 1 µg of poly(dIdC)·poly(dIdC) nonspecific competitor DNA, and specific competitor DNAs where appropriate. Specific 32P end-labeled oligonucleotides (GATA-1, GCAACTGATA AGGATTC (29); Oct1, AATTCACTGG TTCCCAATGA TTTGCATGCT CTCACTTCAC TG; Sp1, GCTAAGGCCC CGCCCCCACC AAGG (30); typically 20 fmols) were then added to a final volume of 30 µl, and the mixture was incubated on ice for 30 min. Binding reactions were then loaded onto a 4% non-denaturing polyacrylamide/0.5 × TBE gel that had been pre-electrophoresed at 200 V until the current across it was 11 mA. After 2 h electrophoresis at 4 °C, gels were dried down and autoradiographed. Laser densitometry was performed with a Molecular Dynamics Computing Densitometer.

The cell cycle position of the peak in GATA-1 DNA binding activity was estimated by using the quantitative FACS data (see, for example, Fig. 1a). 2n and 4n, representing DNA content at the beginning and end of the cell cycle, were defined as the positions of the peaks in fractions 1 and 7, respectively. The n value for the fraction with the highest GATA-1 DNA binding activity was determined relative to these. Peak values from four separate elutriations were used to derive a mean cell cycle position for GATA-1 DNA binding activity.


Fig. 1. MEL cell cycle analysis. a, FACS analysis of propidium iodode-stained log phase MEL cells (top) and elutriated fractions, as described under "Experimental Procedures." Cells containing 2n amounts of DNA were defined as G1 phase cells, those with 2-4n amounts as S phase cells, and those with 4n as G2 and M phase cells. b, cell cycle analysis of elutriated MEL cell fractions. Using data from a Becton-Dickinson FACScan analysis, the percentage of cells from each phase of the cell cycle was determined for each fraction.
[View Larger Version of this Image (16K GIF file)]


Western Blotting

Cell equivalents of cell cycle-fractionated extracts were separated by polyacrylamide gel electrophoresis on 10% SDS-polyacrylamide gel electrophoresis gels and semi-dry electroblotted onto Hybond C+ nitrocellulose (Amersham). GATA-1 protein was immunodetected with anti-mouse GATA-1 antibody (a kind gift of J. D. Engel) after blocking with 5% milk powder in Tris-buffered saline containing 0.05% Tween 20, followed by binding with anti-rabbit IgG-horseradish peroxidase and treatment with ECL (Amersham).

Preparation of Total RNA and Northern Blotting

Total RNA was extracted from elutriated cells by the method of Chomczynski and Sacchi (31), separated on formaldehyde-agarose gels, alkaline blotted onto Hybond N+ membranes (Amersham), and probed with a 32P random hexamer-labeled GATA-1 XhoI fragment.


RESULTS AND DISCUSSION

To perform an analysis of GATA-1 DNA binding activity through the cell cycle, asynchronous MEL cells (27) were fractionated by centrifugal elutriation. This technique separates bulk suspension cells by size and, because cell volume increases through the cell cycle, results in fractionation of cells according to their position in the cell cycle. The cell cycle composition of the fractionation was assessed by FACS analysis of propidium iodide-stained cells taken from each fraction (a typical example is shown in Fig. 1a). The percentages of cells in each phase of the cell cycle for a typical elutriation are summarized in Fig. 1b (cells are defined as G1, S, or G2/M depending on their DNA content (2n, 2-4n, and 4n, respectively)).

We assessed GATA-1 DNA binding activity by electrophoretic mobility shift assay (EMSA). Nuclear proteins, salt extracted from equal numbers of cells through the cell cycle, were incubated with an oligonucleotide containing a strong GATA-1 binding site from the mouse alpha 1 globin promoter (29) and electrophoresed (Fig. 2a, upper panel, lanes 1-7). Nuclear protein from asynchronous MEL cells was also analyzed (lane 8), and the identity of the GATA-1 band shift was confirmed by comparing the effects of specific (self-competition, lane 9) and nonspecific (an oligonucleotide containing a mutated GATA-1 site, lane 10) oligonucleotide competitors. Clearly, there is variation in GATA-1 DNA binding activity per cell through the cell cycle, with low levels in G1 (lanes 1 and 2), an increase to a peak of activity in S phase (lane 5), followed by a decrease in late S/G2 (lanes 6 and 7). Comparison of the FACS profiles for these fractions shows that GATA-1 DNA binding activity is highest in mid-S phase cells (Fig. 1a, fraction 5) compared with early S (Fig. 1a, fraction 4) and late S (Fig. 1a, fraction 6). Quantitation of the GATA-1 band intensities indicates that there is a 4-fold increase in GATA-1 DNA binding activity between early G1 and mid-S phase and an 11-fold decrease between mid-S and G2/M (Fig. 2b).


Fig. 2. GATA-1 DNA binding activity peaks in mid-S phase. a, cell cycle analysis of GATA-1 DNA binding activity. Nuclear protein from equal numbers of elutriated MEL cells was analyzed for binding to a double-stranded end-labeled oligonucleotide containing a strong GATA-1 site by EMSA followed by autoradiography (upper panel, lanes 1-7), as described under "Experimental Procedures." The identity of GATA-1 was confirmed by observing the effects of 50-fold excess unlabeled GATA-1 oligonucleotide self-competition (lane 9) versus competition with an oligonucleotide mutated in the GATA-1 binding site (lane 10). The GATA-1 DNA binding activity of asynchronous MEL cells was also tested (lane 8). Oct1 (middle panel, lanes 1-7) and Sp1 (lower panel, lanes 1-7) DNA binding activities were also measured, and binding specificities were confirmed by self-competition. b, quantitation of transcription factor DNA binding activity per µg of protein through the cell cycle. Band intensities in the above EMSAs were quantitated by laser densitometry and were normalized to the amount of protein per cell through the cell cycle; they are expressed here as a fraction of the peak of GATA-1 binding.
[View Larger Version of this Image (30K GIF file)]


Analysis of GATA-1 DNA binding activity from several different elutriations revealed a consistent peak in mid-S phase. The position of this peak was quantitated by referring to the FACS analysis of each elutriation (see, for example, Fig. 1a). 2n and 4n, representing DNA content at the beginning and end of the cell cycle, were defined as the positions of the G1 and G2/M peaks in fractions 1 and 7, respectively. The n value for the GATA-1 binding peak in each case was calculated relative to these. Data from four separate elutriations yielded a mean value of 2.98n with a standard deviation of 0.04. Thus, GATA-1 binding activity reproducibly peaks in mid-S phase. The drop in GATA-1 DNA binding from mid-S to G2/M was also reproducible, averaging 7-fold in the four elutriations.

To determine whether the variation in GATA-1 DNA binding activity was particular to GATA-1 in this cell line or whether it was a general feature shared with other transcription factors, we determined the DNA binding activity of Oct1 and Sp1, two transcription factors whose cell cycle-regulated DNA binding activity has been characterized previously. Oct1 DNA binding activity has been studied in HeLa cells, and it does not appear to vary relative to bulk protein through the cell cycle except during mitosis, when it loses DNA binding activity (32, 33). We therefore determined Oct1 DNA binding activity in equal numbers of MEL cells by EMSA, using an oligonucleotide containing the octamer motif from the mouse IgH chain gene enhancer (Fig. 2a, middle panel). In contrast to the result seen with GATA-1, Oct1 DNA binding activity does not appear to peak in S phase but instead is highest in the last elutriated fraction, which contains a mixture of G2 and M cells (Fig. 2a, middle panel, lanes 1-7). As cell volume increases through the cell cycle, we conclude that the nuclear concentration of Oct1 competent for DNA binding remains broadly the same, consistent with the published data (32, 33). A second ubiquitous transcription factor, Sp1, has also been shown not to vary in DNA binding activity through the cell cycle in various cell types (34). We therefore sought to determine its activity in MEL cells. An oligonucleotide containing a binding site for Sp1 gave a similar result to Oct1, with the amount of Sp1 DNA binding activity increasing progressively through the cell cycle (Fig. 2a, lower panel). Thus, for two ubiquitously expressed transcription factors, it appears that there is an increase in DNA binding activity concomitant with increasing nuclear volume through the cell cycle, likely maintaining a broadly constant concentration of nuclear protein. In contrast, although GATA-1 DNA binding activity increases in a similar way through to S phase, it contrasts with the other two transcription factors by exhibiting a sharp decrease in activity in late S/G2. GATA-1 revealed a similar profile when we took into account the doubling in nuclear chromatin protein during the cell cycle. Fig. 2b is a plot of the data in Fig. 2a showing the change in DNA binding activities of GATA-1, Oct-1, and Sp1 for equal amounts of nuclear protein through the cell cycle. The DNA binding activities of all three factors increase between G1 and early S. However, GATA-1 DNA binding activity decreases in G2/M (to 9% of peak value), while Oct1 and Sp1 remain high in G2/M (93 and 147% of peak values, respectively).

We next asked whether the S phase peak in GATA-1 DNA binding activity reflected a change in the amount of GATA-1 protein through the cell cycle or whether GATA-1 DNA binding activity was being regulated by some post-translational mechanism, such as phosphorylation. Nuclear protein from equal numbers of cell cycle-fractionated cells was separated by polyacrylamide gel electrophoresis, Western blotted, and probed with an antibody specific for GATA-1 (Fig. 3b). Variation in the amount of GATA-1 protein through the cell cycle can be seen (lanes 1-7), with a peak in mid-S phase (lane 5), in the same fraction where DNA binding activity is at its highest (Fig. 3a, lane 5). Furthermore, the magnitude of the changes in GATA-1 protein and DNA binding activity through the cell cycle is broadly similar. Quantitation of band intensities indicates that between early G1 and mid-S the amount of GATA-1 protein increases 5-fold while DNA binding activity increases 4-fold. Similarly, between mid-S and G2/M the amount of GATA-1 protein decreases 8-fold and DNA binding activity 11-fold. Taken together, these data indicate that the variation in GATA-1 DNA binding activity through the cell cycle is primarily due to variations in the total amount of GATA-1 protein and that post-translational mechanisms make at most a minor contribution to the change in GATA-1 DNA binding activity.


Fig. 3. GATA-1 DNA binding activity, protein and mRNA peak in mid-S phase. a, EMSA of GATA-1 DNA binding through the cell cycle (see Fig. 2 for details). b, the steady state levels of GATA-1 protein peak in mid-S phase. Nuclear protein from elutriated MEL cells was electrophoresed, blotted, and probed with a GATA-1-specific antibody (lanes 1-7). Asynchronous MEL cells were run alongside the cell cycle-fractionated samples (lane 8). c, the steady state level of GATA-1 mRNA peaks in mid-S phase. Total RNA extracted from elutriated MEL cells was size fractionated, Northern blotted, and probed with a GATA-1-specific DNA fragment (upper panel, lanes 1-7). Total RNA from asynchronous cells was included as a control (lane 8). The stained agarose gel is included as a loading control (lower panel).
[View Larger Version of this Image (85K GIF file)]


The varying amounts of nuclear GATA-1 protein through the cell cycle might come about by changes in protein stability, subcellular localization, or gene expression. However, we have assayed GATA-1 DNA binding activity in both nuclear and cytoplasmic extracts and found similar S phase peaks with low levels in G1 and G2/M.2 In particular, we do not detect high levels of GATA-1 DNA binding activity in the cytoplasm in G2/M, which would be expected if the drop in nuclear GATA-1 DNA binding activity we observe in this phase of the cell cycle was due to shuttling between compartments. To investigate the possibility that the variation in the amount of GATA-1 protein was due to changing levels of gene expression, total RNA was extracted from cell cycle-fractionated cells, separated on an agarose gel, Northern blotted, and then probed for GATA-1 message (Fig. 3c). A peak in the level of steady state GATA-1 mRNA was seen in mid-S phase (lane 5), as found for both GATA-1 DNA binding activity and GATA-1 total protein (Fig. 3, a and b, lanes 5). The change in the amount of GATA-1 mRNA (6-fold) between early G1 and mid-S phase is similar to that of protein (5-fold) and DNA binding activity (4-fold). The drop in the level of message between mid-S and G2/M decreases only a little less (4-fold) than protein and mean DNA binding activity (8- and 7-fold, respectively). Thus, the primary control over GATA-1 DNA binding activity appears to be at the RNA level, but there may be some additional control at the protein level.

Variations in DNA binding activity through the cell cycle have been found for ubiquitous transcription factors involved in some of the central events of the cell cycle, including Jun (35), E2F (36), factors regulating the expression of genes involved in DNA synthesis (34, 35), and S phase-specific histone gene expression (19, 37). However, in contrast to these examples, we have now shown that GATA-1, a lineage-restricted transcription factor that targets tissue-specific genes, possesses S phase-specific DNA binding activity in cycling cells. Activation of GATA-1 expression has also been seen in quiescent hematopoietic progenitors upon entrance into the cell cycle (38).

There are several ways in which our observations can be interpreted. One possibility is that GATA-1-directed control of the erythroid program operates through the regulation of erythroid-specific replication origins containing GATA sites, causing early replication and hence gene activation. Since several transcription factors are required as origin-specific replication factors by certain viruses, including Oct1 and beta CCAAT/NF1 family members (39), it is possible that specific replication origins located near to GATA-1-responsive genes may be activated by GATA-1 early in S phase, inducing early replication and subsequent transcriptional activation by GATA-1. An origin of replication has been mapped between the delta  and beta  globin genes of the human beta  globin locus (40), and it is the origin used for early replication of this region in erythroid cells. Furthermore, there is a requirement for the presence of the locus control region, which contains several GATA-1 sites and directs beta  globin gene expression, for early replication of this region of the chromosome (15). However, there is little evidence supporting a role for GATA-1 in eukaryotic origin activity or replication, although it does appear to cause growth inhibition and bind to the origin of replication in Escherichia coli (41). Furthermore, from our data the peak in GATA-1 DNA binding activity (Fig. 2a) occurs too late to fire the beta  globin locus origin early in S phase (19).

A more attractive model based on the correlation between replication timing of genes and their expression (2, 4, 5, 10) positions the effect of GATA-1 DNA binding activity downstream of replication. We envisage that the observed pattern of GATA-1 binding through the cell cycle may be necessary to amplify the effect of early replication on transcriptional activation. As early replicating erythroid genes become stripped of chromatin and active gene complexes, GATA-1 binding sites in regulatory elements, including the locus control region, become available (Fig. 4, left side). By having sufficiently high levels of GATA-1 to compete successfully with the reassembly of repressive chromatin, the expression of GATA-1-activated erythroid genes is maintained. We note that the replication of the locus control region, the major determinant of erythroid expression in MEL cells (14, 19), correlates well with the peak in GATA-1 DNA binding activity.


Fig. 4. Model for activation of GATA-1-responsive genes. Left side, the availability of excess GATA-1 DNA binding activity (triangles) when GATA-1 target genes are replicated allows GATA-1 to compete successfully with repressive chromatin (gray circles). Right side, the decrease in available GATA-1 prevents the activation of non-erythroid genes responsive to other GATA family members.
[View Larger Version of this Image (20K GIF file)]


High levels of GATA-1 throughout S phase could lead to the activation of later replicating genes that are not part of the erythroid program but are normally responsive to other members of the GATA family. Genes containing GATA sites are expressed in a wide range of non-erythroid tissues (22, 42-44). Given the high levels of GATA-1 found in MEL cells, it seems unlikely that passive titration of GATA-1 by binding sites in early replicating activated genes is sufficient to prevent the activation of later replicating genes, as has been suggested for the differential effect of transcription factor IIIA on the expression of somatic and oocyte 5 S RNA genes (4, 17). Instead, we suggest that the decrease in GATA-1 activity that occurs during late S phase is required to prevent activation of non-erythroid genes subject to activation by other GATA family members (Fig. 4, right side). By ensuring that GATA factor availability and target site accessibility occur in the same temporal compartment of S phase, subsets of genes with closely related control sequences can be activated independently.

Finally, another interpretation of these data has been prompted by several recent papers suggesting a role for GATA-1 in control of the cell cycle. Ectopic expression of GATA-1 in both hematopoietic and non-hematopoietic cell lines can lead to alterations in the length of segments of the cell cycle (24). In particular, high levels of ectopic GATA-1 cause S phase to lengthen in NIH3T3 cells, suggesting that the reduction in GATA-1 DNA binding activity we see here may be necessary for the correctly timed exit from S phase. GATA-1 also appears to function as an erythroid survival factor, since differentiation of GATA-1 negative ES cells along the erythroid lineage, or abrogation of GATA-1 activity in MEL cells, leads to premature apoptosis (25, 26). Thus, the high GATA-1 DNA binding activity we see in S phase may be necessary to prevent apoptosis. The emerging picture is that the choice among proliferation, differentiation, and apoptosis is affected by the level of GATA-1. Our data demonstrating a peak of GATA-1 DNA binding activity in mid-S, downstream of the G1/S cell cycle checkpoints, support the idea that GATA-1 has a cell cycle role in erythroid cells.


FOOTNOTES

*   This work was supported by a grant from the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Present address: Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Rd., London SW3 6JB, UK.
§   To whom correspondence should be addressed. Tel.: 44-171-465-5349; Fax: 44-171-497-9078.
1    The abbreviations used are: MEL cells, murine erythroleukemia cells; FACS, fluorescence-activated cell sorting; EMSA, electrophoretic mobility shift assay.
2    M. E. Cullen and R. K. Patient, unpublished observation.

Acknowledgments

We thank Geoff Partington for assistance with some of the early EMSA experiments, Doug Engel for anti-GATA-1 antibody, Rob Nicolas for oligonucleotides, John Pizzey for assistance with analysis, and the ICRF FACS lab for help with cell cycle analysis. We are also grateful to Tariq Enver and Louis Mahadevan for critical reading of the manuscript.


REFERENCES

  1. Till, J. E., McCulloch, E. A., and Siminovitch, L. (1964) Proc. Natl. Acad. Sci. U. S. A. 51, 29-36 [Medline] [Order article via Infotrieve]
  2. Svaren, J., and Chalkley, R. (1990) Trends Genet. 6, 52-56 [CrossRef][Medline] [Order article via Infotrieve]
  3. Wolffe, A. P., and Brown, D. D. (1986) Cell 47, 217-227 [Medline] [Order article via Infotrieve]
  4. Brown, D. D. (1984) Cell 37, 359-365 [Medline] [Order article via Infotrieve]
  5. Villarreal, L. P. (1991) Microbiol. Rev. 55, 512-542
  6. Enver, T., Brewer, A. C., and Patient, R. K. (1988) Mol. Cell. Biol. 8, 1301-1308 [Medline] [Order article via Infotrieve]
  7. Wilson, A. C., and Patient, R. K. (1993) Nucleic Acids Res. 21, 4296-4304 [Abstract]
  8. Proudfoot, N. J., Lee, B. A., and Monks, J. (1992) New Biol. 4, 369-381 [Medline] [Order article via Infotrieve]
  9. Williams, R. D., Lee, B. A., Jackson, S. P., and Proudfoot, N. J. (1996) Nucleic Acids Res. 24, 549-557 [Abstract/Free Full Text]
  10. Holmquist, G. P. (1987) Am. J. Human Genet. 40, 151-173 [Medline] [Order article via Infotrieve]
  11. Calza, R. E., Eckhardt, L. A., DelGiudice, T., and Schildkraut, C. L. (1984) Cell 36, 689-696 [Medline] [Order article via Infotrieve]
  12. Brown, E. H., Iqbal, M. A., Stuart, S., Hatton, K. S., Valinsky, J., and Schildkraut, C. L. (1987) Mol. Cell. Biol. 7, 450-457 [Medline] [Order article via Infotrieve]
  13. Hatton, K. S., Dhar, V., Brown, E. H., Iqbal, M. A., Stuart, S., Didamo, V. T., and Schildkraut, C. L. (1988) Mol. Cell. Biol. 8, 2149-2158 [Medline] [Order article via Infotrieve]
  14. Epner, E., Forrester, W. C., and Groudine, M. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8081-8085 [Abstract]
  15. Forrester, W. C., Epner, E., Driscoll, M. C., Enver, T., Brice, M., Papayannopoulou, T., and Groudine, M. (1990) Genes Dev. 4, 1637-1649 [Abstract]
  16. Wolffe, A. P. (1991) J. Cell Sci. 99, 201-206 [Abstract]
  17. Gottesfeld, J., and Bloomer, L. S. (1982) Cell 28, 781-791 [Medline] [Order article via Infotrieve]
  18. Wormington, W. M., Schlissel, M., and Brown, D. D. (1982) Cold Spring Harbor Symp. Quant. Biol. 47, 879-884
  19. Dhar, V., Mager, D., Iqbal, A., and Schildkraut, C. L. (1988) Mol. Cell. Biol. 8, 4958-4965 [Medline] [Order article via Infotrieve]
  20. Pevny, L., Simon, M. C., Robertson, E., Klein, W. H., Tsai, S. F., Dagati, V., Orkin, S. H., and Costantini, F. (1991) Nature 349, 257-260 [CrossRef][Medline] [Order article via Infotrieve]
  21. Simon, M. C., Pevny, L., Wiles, M. V., Keller, G., Costantini, F., and Orkin, S. H. (1992) Nat. Genet. 1, 92-98 [Medline] [Order article via Infotrieve]
  22. Orkin, S. H. (1992) Blood 80, 575-581 [Medline] [Order article via Infotrieve]
  23. Leonard, M., Brice, M., Engel, J. D., and Papayannopoulou, T. (1993) Blood 82, 1071-1079 [Abstract]
  24. Dubart, A., Romeo, P. H., Vainchenker, W., and Dumenil, D. (1996) Blood 87, 3711-3721 [Abstract/Free Full Text]
  25. Weiss, M. J., and Orkin, S. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9623-9627 [Abstract]
  26. Blobel, G. A., and Orkin, S. H. (1996) Mol. Cell. Biol. 16, 1687-1694 [Abstract]
  27. Friend, C., Scher, W., Holland, J., and Sato, T. (1971) Proc. Natl. Acad. Sci. U.S.A. 68, 378-382 [Medline] [Order article via Infotrieve]
  28. Tate, E. H., Wilder, M. E., Cram, L. S., and Wharton, W. (1983) Cytometry 4, 211-215 [Medline] [Order article via Infotrieve]
  29. Perkins, N. D., Nicolas, R. H., Plumb, M. A., and Goodwin, G. H. (1989) Nucleic Acids Res. 17, 1299-1314 [Abstract]
  30. Lobanenkov, V. V., Nicolas, R. H., Adler, V. V., Paterson, H., Klenova, E. M., Polotskaja, A. V., and Goodwin, G. H. (1990) Oncogene 5, 1743-1753 [Medline] [Order article via Infotrieve]
  31. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 [CrossRef][Medline] [Order article via Infotrieve]
  32. Segil, N., Roberts, S. B., and Heintz, N. (1991) Cold Spring Harbor Symp. Quant. Biol. 56, 285-292 [Medline] [Order article via Infotrieve]
  33. Dalton, S., Coleman, J. R., and Wells, J. (1986) Mol. Cell. Biol. 6, 601-606 [Medline] [Order article via Infotrieve]
  34. Dou, Q. P., Fridovich-Keil, J. L., and Pardee, A. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1157-1161 [Abstract]
  35. Carter, R., Cosenza, S. C., Pena, A., Lipson, K., Soprano, D. R., and Soprano, K. J. (1991) Oncogene 6, 229-235 [Medline] [Order article via Infotrieve]
  36. Nevins, J. R. (1992) Science 258, 424-429 [Medline] [Order article via Infotrieve]
  37. Holthuis, J., Owen, T. A., van Wijnen, A. J., Wright, K. L., Ramsey-Ewing, A., Kennedy, M. B., Carter, R., Cosenza, S. C., Soprano, K. J., Lian, J. B., Stein, J. L., and Stein, G. S. (1990) Science 247, 1454-1457 [Medline] [Order article via Infotrieve]
  38. Sposi, N. M., Zon, L. I., Care, A., Valtieri, M., Testa, U., Gabbianelli, M., Mariani, G., Bottero, L., Mather, C., Orkin, S. H., and Peschle, C. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 6353-6357 [Abstract]
  39. DePamphilis, M. L. (1988) Cell 52, 635-638 [Medline] [Order article via Infotrieve]
  40. Kitsberg, D., Selig, S., Keshet, I., and Cedar, H. (1993) Nature 366, 588-590 [CrossRef][Medline] [Order article via Infotrieve]
  41. Trudel, P., Provost, S., Massie, B., Chartrand, P., and Wall, L. (1996) BioTechniques 20, 684-693 [Medline] [Order article via Infotrieve]
  42. Neave, B., Rodaway, A., Wilson, S. W., Patient, R., and Holder, N. (1995) Mechanisms Dev. 51, 169-182 [CrossRef][Medline] [Order article via Infotrieve]
  43. Yamamoto, M., Ko, L. J., Leonard, M. W., Beug, H., Orkin, S. H., and Engel, J. D. (1990) Genes Dev. 4, 1650-1662 [Abstract]
  44. Laverriere, A. C., MacNeill, C., Mueller, C., Poelmann, R. E., Burch, J. B. E., and Evans, T. (1994) J. Biol. Chem. 269, 23177-23184 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.